Clinical Trial Update: Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 [Phase 3]

View source ↗

Summary

This document reports on the completion of a long-term Phase 3 study evaluating self-injected certolizumab pegol (CDP870) in adults with active rheumatoid arthr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Active Rheumatoid Arthritis | Phase 3 | Status: COMPLETED